Antiretroviral resistance in human immunodeficiency virus infection

被引：0

作者：

Afani S, Alejandro ^{[1
]}

Gallardo O, Ana M. ^{[1
]}

机构：

[1] Univ Chile, Hosp Clin, Dept Med Interna, Secc Inmunol, Santiago, Chile

来源：

REVISTA CHILENA DE INFECTOLOGIA | 2011年 / 28卷 / 05期

关键词：

drug resistance; antiretroviral therapy; mutation; DRUG-RESISTANCE; HIV; MECHANISMS; INHIBITORS; REVEALS; TYPE-1;

D O I：

10.4067/S0716-10182011000600011

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Resistance to anti-retroviral therapy is one of the main problems in the favorable outcome of treatment in HIV patients, as well as toxicity and adherence to treatment. Resistance has increased in recent years, and it is evaluated through genotyping and phenotypic tests. Information provided by these studies is crucial when deciding the most appropriate treatment. However, genotype interpretation is complex and subject to frequent change, because of the incorporation of new drugs and the appearance of new resistance patterns. This review aims,understanding the fundamental concepts of antiretroviral resistance (ARV), which examines the general principles, mechanisms and patterns of resistance, both for the traditional family of anti-retrovirals, as well as for the most recently licensed drugs.

引用

页码：461 / 469

页数：9

共 28 条

[1] Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41 [J].

Anastassopoulou, Cleo G. ;

Ketas, Thomas J. ;

Klasse, Per Johan ;

Moore, John P. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (13) :5318-5323

[2]

[Anonymous], 18 C RETR OPP INF CR

[3] HIV entry inhibitors: mechanisms of action and resistance pathways [J].

Briz, V ;

Poveda, E ;

Soriano, V .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (04) :619-627

[4] Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen [J].

Cabrera, Cecilia ;

Marfil, Silvia ;

Garcia, Elisabet ;

Martinez-Picado, Javier ;

Bonjoch, Anna ;

Bofill, Margarita ;

Moreno, Santiago ;

Ribera, Esteban ;

Domingo, Pere ;

Clotet, Bonaventura ;

Ruiz, Lidia .

AIDS, 2006, 20 (16) :2075-2080

[5]

Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195

[6] Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection [J].

Faetkenheuer, Gerd ;

Nelson, Mark ;

Lazzarin, Adriano ;

Konourina, Irina ;

Hoepelman, Andy I. M. ;

Lampiris, Harry ;

Hirschel, Bernard ;

Tebas, Pablo ;

Raffi, Francois ;

Trottier, Benoit ;

Bellos, Nicholaos ;

Saag, Michael ;

Cooper, David A. ;

Westby, Mike ;

Tawadrous, Margaret ;

Sullivan, John F. ;

Ridgway, Caroline ;

Dunne, Michael W. ;

Felstead, Steve ;

Mayer, Howard ;

van der Ryst, Elna .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (14) :1442-U46

[7]

Geretti AM, 2006, AIDS REV, V8, P210

[8] Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults [J].

Jacobson, JM ;

Lowy, I ;

Fletcher, CV ;

O'Neill, TJ ;

Tran, DNH ;

Ketas, TJ ;

Trkola, A ;

Klotman, ME ;

Maddon, PJ ;

Olson, WC ;

Israel, RJ .

JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (01) :326-329

[9]

Johnson Victoria A, 2010, Top HIV Med, V18, P156

[10]

JONES G, 2007, 14 C RETR OPP INF LO

← 1 2 3 →